India Glycols Limited intimated a board meeting on 13 November 2026 to consider half-yearly unaudited standalone and consolidated financial results for the period ended September 2026. Trading window closes 1 October to 15 November 2026.
India Glycols disclosed that IGL Spirits received BSE and NSE listing approval for 6.70 crore demerger shares. Trading in these equity shares begins on 4 November 2026.
India Glycols Limited clarified that it has no undisclosed material information regarding recent share price movements. The company attributes the price fluctuation to market-driven factors.
India Glycols Ltd has submitted the quarterly certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018. The document was received from its Registrar, MCS Share Transfer Agent.
India Glycols Limited announced that its subsidiary, IGL Spirits Limited, approved share allotment under a Scheme of Arrangement and appointed new key managerial personnel.
India Glycols Ltd announced that four senior management personnel ceased their roles following the effective date of a previously disclosed Scheme of Arrangement.
India Glycols Limited has completed its demerger into three separate entities effective September 1, 2026. The scheme, sanctioned by the NCLT, is now operational.
India Glycols' subsidiary, Ennature Bio Pharma, announced the appointment of new Directors and a Managing Director. These appointments are part of ongoing corporate updates.
India Glycols Ltd received the certified NCLT order approving the Scheme of Arrangement, which involves the demerger of its Biopharma, Spirits, and Biofuel undertakings.
India Glycols Limited clarified that there is no undisclosed information causing the recent increase in trading volume. The company attributes the surge to market forces.
India Glycols posted a record Q1 with 19% net revenue growth and 32% PAT growth, driven by its Bio-Pharma segment. Management is aggressively pivoting toward a premium-led consumer model through restructuring and new liquor brand partnerships.
India Glycols reported strong Q1FY27 results with 19% Gross Revenue growth and 32% PAT growth, driven by a diversified portfolio and a demerger strategy into three focused platforms.
India Glycols is sending a reminder to physical security holders to update their PAN, KYC, and nomination details as per SEBI regulations. This is a routine compliance communication.
India Glycols Ltd re-designated Ms. Pragya Bhartia Barwale from Whole Time Director and KMP to Non-Executive Non-Independent Director, effective August 12, 2026.
India Glycols has scheduled a board meeting for August 12, 2026, to approve the company's unaudited financial results for the first quarter ended June 30, 2026.
Shri Akshay Bansal, a Senior Managerial Personnel (SMP) at India Glycols Limited, has been transferred to its subsidiary, Ennature Bio Pharma Limited, as an Executive Director.
India Glycols Limited has shared the web-link for accessing the 42nd AGM Notice and Annual Report for FY 2025-26 with shareholders having unregistered email addresses.
India Glycols Ltd submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report forms part of the company's annual report.
India Glycols Limited has issued a notice for its Annual General Meeting on August 19, 2026. The meeting will cover financial statements and dividend confirmation.
India Glycols Limited has scheduled its 42nd Annual General Meeting for August 19, 2026, via video conferencing. Relevant notices and annual reports will be circulated to shareholders.
NCLT Allahabad Bench has sanctioned India Glycols Limited's demerger scheme. The Bio Pharma, Spirits, and Biofuel undertakings will be transferred to resulting companies EBL and ISL.
India Glycols reported a strong FY26 with net revenue of ₹4,211cr (up 11.8%) and PAT of ₹293cr (up 26.8%). Strategy focuses on premiumization in spirits and expanding bio-based chemicals.
India Glycols filed for mediation to recover a ₹79.76 Crore insurance claim against New India Assurance. The claim relates to material damage and business losses.